Pharmaceuticals & Therapeutics

Par Health's new ready-to-use Sugammadex syringe tackles medication errors and workflow delays, signaling a major shift in how essential medicines are delivered.

Solid Q2 earnings are just the start. Photocure is moving beyond its core imaging tech with key acquisitions and AI partnerships, building a full-spectrum platform.

Shionogi launches XOCOVA, the first oral pill to prevent COVID after exposure. With a 67% efficacy rate and a $1,400 price tag, who will it protect?

Firefly's AI brain mapping joins Next Health's peptide therapies, spurred by a key FDA panel vote. Is this the future of cognitive care or a risky leap?

Dasher Neuroscience completes Phase 2 enrollment for its AI-designed drug for MSA, a fatal disease with no cure, signaling a major step toward a first-in-class therapy.

Two small firms just secured a patent until 2045 on a decades-old drug. It's a masterclass in strategy, revealing the future of pharmaceutical value.

An Australian biotech's breakthrough study on fucoidan, a seaweed compound, offers a safe, clinically-proven new option for men suffering from BPH.

A new partnership in the booming peptide market signals a major shift. Novadose and Pure Pharmaceuticals are betting that future success won't just come from discovery, but from demonstrating unimpeachable quality and transparency.

A novel partnership aims to create the first drug for ReNU syndrome, a condition found in 2024, potentially redefining rare disease drug development.

A breakthrough trial for a rare genetic disorder unlocks $50M in funding. We explore the novel RNA science, the savvy investment, and why it's all happening in Australia.

Leveraging its global dominance in human medicine, Jiangxi Bio is entering the booming veterinary market with a new production line, a key move in its growth strategy.

A positive EMA opinion for Minoryx's NEZGLYAL offers the first-ever drug therapy for a fatal childhood disease, highlighting a key regulatory pathway.

Ipsen's BOLD trial for biliary atresia failed, a blow to families. But in the data from this setback lies a critical roadmap for future research.

Taiwan's Jyong Biotech touts a global licensing strategy for its BPH drug, but a closer look reveals significant clinical setbacks and financial pressures.

A Korean biotech is betting big on the U.S. market with its new GERD drug. A deal with manufacturer Bora Pharmaceuticals is the first step. Is it enough?

With a billion people globally struggling with sleep apnea and CPAP compliance low, Incannex Healthcare is advancing its oral drug IHL-42X, now in a key Phase 2 study.

A scientific breakthrough reveals a reversible cause for sarcopenia, offering the first real hope for a drug therapy to restore strength for millions of seniors.

As the pet care market booms, Exubrion Therapeutics appoints a new CCO to expand its groundbreaking, single-injection arthritis treatment for dogs.

With an oversubscribed $130M Series B, Crystalys Therapeutics is accelerating its gout drug, dotinurad. But can it win the race to serve millions?

A new partnership between Evogene and ELEO leverages AI and natural product science to create an oral PCSK9 inhibitor, aiming to disrupt a $23B market.